VARIATIONS IN IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN OVEREXPRESSION IN CERVICAL CARCINOMAS WITH DIFFERENT ANTIBODIES AND METHODS OF DETECTION

被引:112
作者
LAMBKIN, HA
MOTHERSILL, CM
KELEHAN, P
机构
[1] NATL MATERN HOSP,DEPT PATHOL,DUBLIN 2,IRELAND
[2] DUBLIN INST TECHNOL,DEPT BIOL,DUBLIN 8,IRELAND
关键词
P53; IMMUNOCYTOCHEMISTRY; ANTIGEN RETRIEVAL; CERVICAL CARCINOMA;
D O I
10.1002/path.1711720105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunocytochemical detection of p53 protein products in paraffin sections is possible with a number of antisera, monoclonal and polyclonal. Few corroborative results amongst different laboratories have been published due to variations in the antibodies, the fixation protocols, and the immunocytochemical methods applied. Antigen unmasking methods employing microwaves or proteolytic enzymes add to the disparity in the percentage of positive cases reported. In this study, paraffin sections of 55 cases of cervical carcinoma were immunostained with monoclonal antibodies p53-DO7 and p53-1801 (a) without section pretreatment, (b) with pronase digestion, and (c) with microwave antigen retrieval in citric acid buffer. Specimens fixed in buffered formalin required antigen unmasking to show positive staining. Pronase digestion caused false-negative immunostaining. Microwave pretreatment with p53-DO7 yielded 100 per cent positivity for p53 proteins but only 7/55 cases with more than 50 per cent positive cells. Monoclonal antibody p53-DO7 detected more positive cases than p53-1801. Immunostaining with antibodies to p53 proteins must be interpreted cautiously as variations in fixation, antibodies, and section pretreatment will significantly affect results.
引用
收藏
页码:13 / 18
页数:6
相关论文
共 25 条
[1]   P53 AND C-ERBB-2 PROTEIN EXPRESSION IN BREAST CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY INCLUDING CORRELATIONS WITH RECEPTOR STATUS, PROLIFERATION MARKERS, AND CLINICAL STAGE IN HUMAN BREAST-CANCER [J].
BARBARESCHI, M ;
LEONARDI, E ;
MAURI, FA ;
SERIO, G ;
PALMA, PD .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1992, 98 (04) :408-418
[2]   HUMAN P53 IS PHOSPHORYLATED BY P60-CDC2 AND CYCLIN-B-CDC2 [J].
BISCHOFF, JR ;
FRIEDMAN, PN ;
MARSHAK, DR ;
PRIVES, C ;
BEACH, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) :4766-4770
[3]  
BORRESEN AL, 1992, LANCET, V339, P1350
[4]  
BUSBYEARLE RMC, 1992, LANCET, V339, P1350, DOI 10.1016/0140-6736(92)91993-I
[5]   CLONAL P53 MUTATION IN PRIMARY CERVICAL-CANCER - ASSOCIATION WITH HUMAN-PAPILLOMAVIRUS-NEGATIVE TUMORS [J].
CROOK, T ;
WREDE, D ;
TIDY, JA ;
MASON, WP ;
EVANS, DJ ;
VOUSDEN, KH .
LANCET, 1992, 339 (8801) :1070-1073
[6]   WILD-TYPE P53 CAN INHIBIT ONCOGENE-MEDIATED FOCUS FORMATION [J].
ELIYAHU, D ;
MICHALOVITZ, D ;
ELIYAHU, S ;
PINHASIKIMHI, O ;
OREN, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8763-8767
[7]   INDUCTION OF APOPTOSIS IN FIBROBLASTS BY C-MYC PROTEIN [J].
EVAN, GI ;
WYLLIE, AH ;
GILBERT, CS ;
LITTLEWOOD, TD ;
LAND, H ;
BROOKS, M ;
WATERS, CM ;
PENN, LZ ;
HANCOCK, DC .
CELL, 1992, 69 (01) :119-128
[8]  
HALL PA, 1993, ONCOGENE, V8, P203
[9]   INCREASED AGE AND MORTALITY ASSOCIATED WITH CERVICAL CARCINOMAS NEGATIVE FOR HUMAN PAPILLOMAVIRUS RNA [J].
HIGGINS, GD ;
DAVY, M ;
RODER, D ;
UZELIN, DM ;
PHILLIPS, GE ;
BURRELL, CJ .
LANCET, 1991, 338 (8772) :910-913
[10]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53